文献速递物质与行为成瘾

司美格鲁肽与利拉鲁肽用于酒精使用障碍的再定位研究

Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder.
PubMed 文献 · JAMA Psychiatry · 2025-01-01

瑞典全国性观察性队列研究纳入227866例酒精使用障碍(AUD)患者,比较同一人使用与未使用胰高血糖素样肽-1受体激动剂(GLP-1)期间AUD住院风险。司美格鲁肽(4321人)调整后风险比(aHR)0.64(95%CI 0.50-0.83),利拉鲁肽(2509人)aHR 0.72(95%CI 0.57-0.92),均低于获批AUD药物(aHR 0.98;95%CI 0.96-1.00)。作者认为两者可能有效,亟需临床试验确认。

要点

  • 司美格鲁肽使用期AUD住院风险aHR 0.64(95%CI 0.50-0.83),为所比较药物中最低。
  • 利拉鲁肽使用期AUD住院风险aHR 0.72(95%CI 0.57-0.92)。
  • 获批AUD药物使用期风险仅轻度降低(aHR 0.98;95%CI 0.96-1.00)。

核心结论

  • 在合并肥胖或2型糖尿病的AUD患者中,使用司美格鲁肽和利拉鲁肽与AUD住院风险显著降低相关,且低于正式获批的AUD药物。
  • 作者认为司美格鲁肽和利拉鲁肽可能对AUD治疗有效,亟需临床试验确认这些发现。

研究设计与样本

  • 这是一项在瑞典全国开展的观察性队列研究,使用2006年1月至2023年12月的数据。
  • 队列从住院医疗、专科门诊医疗、病假和残疾抚恤金登记中识别,纳入所有16至64岁、诊断为AUD的居民。
  • 队列共纳入227866例AUD患者,其中男性144714人(63.5%)、女性83154人(36.5%),平均(SD)年龄40.0(15.7)岁,中位(IQR)随访时间8.8(4.0-13.3)年。
  • 主要暴露为使用单个GLP-1激动剂(与未使用GLP-1激动剂相比),次要暴露为有AUD适应症的药物。
  • 主要结局为AUD住院,采用个体内Cox回归模型分析;次要结局为任何物质使用障碍(SUD)相关住院、躯体住院和自杀未遂。

主要发现

  • 共133210人(58.5%)发生AUD住院。
  • 司美格鲁肽(4321名使用者)与最低风险相关:AUD住院aHR 0.64(95%CI 0.50-0.83),任何SUD住院aHR 0.68(95%CI 0.54-0.85)。
  • 利拉鲁肽(2509名使用者)与第二低风险相关:AUD住院aHR 0.72(95%CI 0.57-0.92),任何SUD住院aHR 0.78(95%CI 0.64-0.97)。
  • 使用任何AUD药物与风险轻度降低相关(aHR 0.98;95%CI 0.96-1.00)。
  • 司美格鲁肽(aHR 0.78;95%CI 0.68-0.90)和利拉鲁肽(aHR 0.79;95%CI 0.69-0.91)使用与躯体住院风险降低相关,但与自杀未遂无关(司美格鲁肽:aHR 0.55;95%CI 0.23-1.30;利拉鲁肽:aHR 1.08;95%CI 0.55-2.15)。

关键数值与推荐

  • 司美格鲁肽使用期AUD住院aHR 0.64(95%CI 0.50-0.83),任何SUD住院aHR 0.68(95%CI 0.54-0.85)。
  • 利拉鲁肽使用期AUD住院aHR 0.72(95%CI 0.57-0.92),任何SUD住院aHR 0.78(95%CI 0.64-0.97)。
  • 任何AUD药物使用期AUD住院aHR 0.98(95%CI 0.96-1.00)。
  • 司美格鲁肽使用期躯体住院aHR 0.78(95%CI 0.68-0.90),利拉鲁肽aHR 0.79(95%CI 0.69-0.91)。
  • 自杀未遂:司美格鲁肽aHR 0.55(95%CI 0.23-1.30),利拉鲁肽aHR 1.08(95%CI 0.55-2.15)。

临床怎么用

  • 作者认为司美格鲁肽和利拉鲁肽可能对AUD治疗有效,并指出亟需临床试验确认这些发现。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Preliminary studies suggest that glucagon-like peptide-1 receptor (GLP-1) agonists, used to treat type 2 diabetes and obesity, may decrease alcohol consumption. OBJECTIVE: To test whether the risk of hospitalization due to alcohol use disorder (AUD) is decreased during the use of GLP-1 agonists compared with periods of nonuse for the same individual. DESIGN, SETTING, AND PARTICIPANTS: This cohort study was an observational study conducted nationwide in Sweden using data from January 2006 to December 2023. The population-based cohort was identified from registers of inpatient care, specialized outpatient care, sickness absence, and disability pension. Participants were all residents aged 16 to 64 years who had a diagnosis of AUD. EXPOSURES: The primary exposure was use of individual GLP-1 agonists (compared with nonuse of GLP-1 agonists), and the secondary exposure was medications with indication for AUD. MAIN OUTCOMES AND MEASURES: The primary outcome was AUD hospitalization analyzed in a Cox regression within-individual model. Secondary outcomes were any substance use disorder (SUD)-related hospitalization, somatic hospitalization, and suicide attempt. RESULTS: The cohort included 227 866 individuals with AUD; 144 714 (63.5%) were male and 83 154 (36.5%) were female, with a mean (SD) age of 40.0 (15.7) years. Median (IQR) follow-up time was 8.8 (4.0-13.3) years. A total of 133 210 individuals (58.5%) experienced AUD hospitalization. Semaglutide (4321 users) was associated with the lowest risk (AUD: adjusted hazard ratio [aHR], 0.64; 95% CI, 0.50-0.83; any SUD: aHR, 0.68; 95% CI, 0.54-0.85) and use of liraglutide (2509 users) with the second lowest risk (AUD: aHR, 0.72; 95% CI, 0.57-0.92; any SUD: aHR, 0.78; 95% CI, 0.64-0.97) of both AUD and SUD hospitalization. Use of any AUD medication was associated with a modestly decreased risk (aHR, 0.98; 95% CI, 0.96-1.00). Semaglutide (aHR, 0.78; 95% CI, 0.68-0.90) and liraglutide (aHR, 0.79; 95% CI, 0.69-0.91) use were also associated with decreased risk of somatic hospitalizations but not associated with suicide attempts (semaglutide: aHR, 0.55; 95% CI, 0.23-1.30; liraglutide: aHR, 1.08; 95% CI, 0.55-2.15). CONCLUSIONS AND RELEVANCE: Among patients with AUD and comorbid obesity/type 2 diabetes, the use of semaglutide and liraglutide were associated with a substantially decreased risk of hospitalization due to AUD. This risk was lower than that of officially approved AUD medications. Semaglutide and liraglutide may be effective in the treatment of AUD, and clinical trials are urgently needed to confirm these findings.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Lähteenvuo M, Tiihonen J, Solismaa A, et al. Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder. JAMA Psychiatry. 2025. PMID: 39535805. doi:10.1001/jamapsychiatry.2024.3599

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。